Jun 07, 2023 / 07:00PM GMT
Shreya Chowdhry - Jefferies - Analyst
I think we're good. Good evening, everyone, and welcome to the 2023 Jefferies Global Healthcare Conference. My name is Shreya Chowdhry from the Jefferies investment banking team, and it's my great pleasure to introduce to you today, the CEO and President of Viracta Therapeutics, Mark Rothera.
Mark Rothera - Viracta Therapeutics, Inc. - President & CEO
Good afternoon, and thank you very much to Jefferies for the invitation to speak at the conference today. Viracta was founded in 2015, and it's been a public company since 2021. And our mission is to treat and prevent virus-associated cancer. During the course of the presentation, I may make some forward-looking statements.
So, really for today's presentation, my focus is going to be on Nana-val, which is our lead clinical stage program, which is focused on treating EBV-associated cancers, Epstein-Barr virus associated cancers. And this lead program, Nana-val, is an all-oral combination of nanatinostat, which is an HDAC inhibitor that is being used in this purpose
Viracta Therapeutics Inc at Jefferies Healthcare Conference Transcript
Mar 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers